Besides, Okada et al. conducted a phase I cohort study to evaluate the safety and immunogenicity of a synthetic peptide vaccine targeting GAA epitopes, including IL-13Rα2, EphA2, WT1, and Survivin, by subcutaneous injection in patients with WHO grade 2 gliomas [97]. This evidence concerns the gene IL13RA2 and central nervous system cancer.